Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Go back to Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.73 -0.15 (1.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.88 | 52 Week High | $117.12 | |||
| Open | $14.77 | 52 Week Low | $46.52 | |||
| Day High | $15.19 | P/E | N/A | |||
| Day Low | $14.56 | EPS | $-1.97 | |||
| Volume | 1,686,044 | |||||
